Founding partner and chairman of Huagai Capital
Mr. Xu Xiaolin received a bachelor's degree in international economics at Peking University, EMBA at Peking University, founding partner and chairman of Huagai Capital. Prior to the creation of Huagai Capital, Mr. Xu Xiaolin was the general manager of CCB International Wealth Management Co., Ltd. (CCBI), director and chief investment officer of CCB International Asset Management Co., Ltd. and the founder of CCB International Medical Fund. Successfully set up the first domestic RMB fund of medical treatment industry -- medical fund CCB International Management Department of China Construction Bank, the total scale of the fund is up to 15 billion. Prior to that, also served as general manager of the merger of Great Wall Securities. Mr. Xu Xiaolin also serves as the first executive chairman of "Bright • China", the president of China Venture Capital and China Venture Capital Students Association, the sponsor and first rotating chairman of China's 50th Medical and Health Investment Forum, and a scientist investor of Chinese pharmaceutical enterprises, the rotating president of the conference.
Mr. Xu Xiaolin led and participated in nearly 70 large-scale domestic and foreign investment items, including Harmonicare Medica, Bybo Dental, Cologne Pharma, Buchang Pharma, East Sunshine Pharma, Lu Yan Pharma, Kant Lai, Chengda Biology, Kangtai Biology, Doctor, Great Soft, Zhonghe Pharma, Fuhong Hanlin, Zheng Guangxing, Nokangda, Sino Vision, Baodao Maternity Hospital, Hagia, Deqi Pharma , etc. And won " Top 100 Investors of China of Zero2IPO Group in 2017" , “ Top 10 Investors in China Medical and Health Care Industry of Chinaventure Group in 2016 and 2017"Top 50 Investors in China FT Excellence 2016 and 2017".